BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 11302550)

  • 1. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.
    Anderson JE; Appelbaum FR; Schoch G; Barnett T; Chauncey TR; Flowers ME; Storb R
    Biol Blood Marrow Transplant; 2001; 7(3):163-70. PubMed ID: 11302550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
    Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
    Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.
    Lawton CA; Cohen EP; Murray KJ; Derus SW; Casper JT; Drobyski WR; Horowitz MM; Moulder JE
    Bone Marrow Transplant; 1997 Dec; 20(12):1069-74. PubMed ID: 9466280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation.
    Labar B; Bogdanić V; Nemet D; Mrsić M; Vrtar M; Grgić-Markulin L; Kalenić S; Vujasinović S; Presecki V; Jakić-Razumović J
    Bone Marrow Transplant; 1992 May; 9(5):343-7. PubMed ID: 1617318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
    Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
    Kalaycioglu ME; Bolwell BJ
    Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT).
    Corvò R; Lamparelli T; Bruno B; Barra S; Van Lint MT; Vitale V; Bacigalupo A
    Bone Marrow Transplant; 2002 Dec; 30(11):717-23. PubMed ID: 12439693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
    Bär BM; Schattenberg A; De Man AJ; Hoogenhout MJ; Boezeman J; de Witte T
    Bone Marrow Transplant; 1992 Jul; 10(1):45-52. PubMed ID: 1515878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
    Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
    Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
    Woods WG; Ramsay NK; Weisdorf DJ; Haake R; Vallera DA; Kim TH; Lasky L; Nesbit ME; Bostrom B; Uckun F
    Bone Marrow Transplant; 1990 Jul; 6(1):9-16. PubMed ID: 2202462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
    Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.